Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Leases (2016 - 2024)

Historic Capital Leases for Niagen Bioscience (NAGE) over the last 14 years, with Q3 2024 value amounting to $2000.0.

  • Niagen Bioscience's Capital Leases fell 8571.43% to $2000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $2000.0, marking a year-over-year decrease of 8571.43%. This contributed to the annual value of $12000.0 for FY2023, which is 4545.45% down from last year.
  • Latest data reveals that Niagen Bioscience reported Capital Leases of $2000.0 as of Q3 2024, which was down 8571.43% from $6000.0 recorded in Q2 2024.
  • Niagen Bioscience's Capital Leases' 5-year high stood at $36000.0 during Q1 2020, with a 5-year trough of $2000.0 in Q3 2024.
  • For the 5-year period, Niagen Bioscience's Capital Leases averaged around $16076.9, with its median value being $14000.0 (2023).
  • Per our database at Business Quant, Niagen Bioscience's Capital Leases surged by 1111.11% in 2020 and then crashed by 8571.43% in 2024.
  • Niagen Bioscience's Capital Leases (Quarter) stood at $20000.0 in 2020, then tumbled by 45.0% to $11000.0 in 2021, then surged by 100.0% to $22000.0 in 2022, then crashed by 45.45% to $12000.0 in 2023, then plummeted by 83.33% to $2000.0 in 2024.
  • Its Capital Leases stands at $2000.0 for Q3 2024, versus $6000.0 for Q2 2024 and $9000.0 for Q1 2024.